Mary Crowley Partners with Velos eResearch and Net.Orange Systems

Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems

FREMONT, Calif., Feb. 26 /PRNewswire/-Velos, Inc., the recognized leader and trusted resource for clinical research management information systems, and Net.Orange, Inc., the respected healthcare Internet solutions company, have partnered with the highly-regarded Mary Crowley Cancer Research Centers (Mary Crowley). The two companies have helped Mary Crowley to achieve best practices for strong central clinical research infrastructure and implementation of an enterprise-wide system of financial responsibility.
 
"We are happy to reach this level of accomplishment," said David Shanahan President of Mary Crowley. "Our historic mission depends on fiscal responsibility and Velos eResearch has given us the tools to ensure order, compliance and sustainability in our financial affairs. This only enhances our ability to serve others with continued dedication in the years to come."
 
As inventor of the revolutionary cOSx2122; (Clinical Operating System), as well as many general and therapeutic-specific technology solutions, Net.Orange began strategic collaboration with Mary Crowley in Fall 2006 in deploying these applications.
 
Net.Orange partnered with Velos in 2006 to better serve research institutions. Using Velos eResearch and the Net.Orange cOSx2122;, Mary Crowley has seamlessly merged its research and financial operations, and completely automated its research billing. As a result, investigators now have an accurate financial picture of research activity integrated with patient care activity. The management team also has better visibility of operational bottlenecks that prevent on-time billing. This solution has been operational for a full year and has led to consistent on-time billing, accurate budgeting and compliance with research billing practices.
 
During the past two years, Mary Crowley has used Velos eResearch and the Net.Orange cOSx2122; solution for clinical trial management to administer more than 200 cancer trials across a national network of 10 cancer centers. Mary Crowley connects disparate systems, including Velos eResearch, to provide critical information access to internal and external roles in the clinical trials process.
 
Dr. Vasu Rangadass, Net.Orange CEO and Founder added, "We are very pleased that we could partner with Velos in serving the Mary Crowley Cancer Research Centers. Bringing our two systems together helped them to extend their clinical research processes and tie them to other parts of the business."

"We are equally excited about these achievements," stated Velos President and CEO, John S. McIlwain.  "Mary Crowley Cancer Research Centers have made full use of the financial improvement capabilities of Velos eResearch. We applaud the initiative they took throughout and we know they will continue to be progressive in applying advanced technology to clinical research information challenges."
 
About the Mary Crowley Cancer Research Centers
Exploring investigational vaccine, gene, and cellular therapies with the goal of expanding treatment options for all cancer patients is the primary mission of the Mary Crowley Cancer Research Centers (Mary Crowley). Mary Crowley has performed hundreds of Phase I and Phase II clinical trial protocols, treated more than 3,000 patients, explored more than 100 new agents, and accomplished more than 140 FDA-approved clinical trials. The 501(c)(3) organization was established in 1992, is headquartered in Dallas and coordinates ten affiliate facilities nationwide. For more information, visit www.marycrowley.org
About Net.Orange
Founded on the imperative of turning data into information and then information into knowledge in a corporate environment, Net.Orange is passionate about how that dynamic is brought into the healthcare arena.  The company is committed to the objective of helping customers provide superior quality patient care through better decision making and improved productivity. Net.Orange offers solutions and services that are modular, extensible, and interoperable, with lower cost of ownership and ease of use. The Net.Orange Clinical Operating Systemx2122; (cOSx2122;) is an intelligent collaboration hub that connects patients, providers, and payers through a consistent common representation. Net.Orange is headquartered in Irving, Texas.  For more information, visit www.ndorange.com
 
About Velos
Velos is the trusted clinical trial management resource for investigators, sponsors and research institutions of all sizes throughout the U.S.  Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. The system fundamentally improves the way data is collected, organized and shared. Velos applies rigorous software quality assurance (SQA) standards in its software development process and is the only software vendor in widespread use at investigator sites that is also CFR Part 11 compliant. A pure Internet technology platform, Velos eResearch harnesses advanced powers of the Internet to enable research sites, sponsors, and patients to participate in a secure, integrated system platform.  System users are freed of redundant data entry and related time delays associated with most clinical research today. With emphasis on workflow, Velos integrates the clinical, administrative and financial information needs of research management. Velos eTools, a companion product to Velos eResearch, empowers customers by giving them ownership and access to functions such as system configuration, data migrations, custom reporting and third party data submissions.  Founded in 1996, Velos is privately held with headquarters in Fremont, California.  For more information, visit www.velos.com
 
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.